Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma
| Autor: | S. Zeil, U. Schwanebeck, C. Vogelberg |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Budesonide
Male medicine.medical_specialty medicine.medical_treatment Pharmaceutical Science Placebo Gastroenterology Double-Blind Method Internal medicine Drug Discovery medicine Humans Exhaled breath condensate Anti-Asthmatic Agents Respiratory system Expectorant Child Children Asthma Pharmacology Productive Cough Cross-Over Studies business.industry Hedera Plant Extracts medicine.disease Ivy leaves dry extract Bronchodilator Agents Plant Leaves Cough Complementary and alternative medicine Anesthesia Molecular Medicine Drug Therapy Combination Female Cough medicine business medicine.drug |
| Zdroj: | Phytomedicine. 21(10):1216-1220 |
| ISSN: | 0944-7113 |
| DOI: | 10.1016/j.phymed.2014.05.006 |
| Popis: | Ivy leaves dry extract is registered as an expectorant in patients with respiratory diseases associated with productive cough. Next to its secretolytical properties, bronchospasmolytical effects are described. However only limited data exist about a possible therapeutical effect in asthmatic patients. In this double blind, placebo-controlled, randomized cross-over study, 30 children (median age 9.07 years (min-max: 6-11)) suffering from partial or uncontrolled mild persistent allergic asthma despite long-term treatment with 400 μg budesonide equivalent were investigated. After a four week run-in period, patients either received ivy leaves dry extract for four weeks in addition to their inhaled corticosteroid therapy or placebo, followed by a wash-out phase before switching to the other treatment arm. Lung function, FeNO, exhaled breath condensate pH and life quality was analyzed after each treatment period. There was a significant improvement of MEF(75-25), MEF25 and VC after treatment with ivy leaves dry extract (MEF(75-25) change in the mean 0.115 l/s, p=0.044; MEF25 change in the mean 0.086 l/s, p=0.041; VC change in the mean 0.052 l, p=0.044), but not after treatment with placebo. For the primary outcome parameters (relative change of FEV1 and MEF(75-25) before bronchodilation) no treatment effect could be detected in the cross-over analysis (FEV1 p=0.6763 and MEF(75-25) p=0.6953). This proof-of-concept study indicates that children with mild uncontrolled asthma despite regular inhaled corticosteroid therapy might benefit from an additional therapy with ivy leaves dry extract. However, further studies are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect